Unranked

InMed Pharmaceuticals Inc.

INM

$1.565

+0.32% (24h)

Last updated: 1 second ago

Market Cap

$5.19M

Volume (24h)

5.05K

Last Close (7D)

$1.57

View on TradingView

Price Chart

Company Profile

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

Website

www.inmedpharma.com

Country

🇨🇦 Canada

A Vancouver-based pharma company developing drugs from rare cannabinoids (CBN, CBG, CBC) that plants produce in tiny quantities — using biosynthesis to manufacture them at pharmaceutical scale.

🧬 BioSynt platform synthesizes rare cannabinoids chemically, bypassing the limitations of plant extraction entirely

Key Stats

52-Week Range

$0.58$5.50

Beta0.97

Trailing P/EN/A

Forward P/E-0.25

Trailing EPS-1.47

Avg Volume1.67M

Enterprise Value$389.53K

Shares Outstanding3.31M

Earnings & Analyst

Next Earnings2026-05-12

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Latest News

SeekingAlpha · May 25, 2026
InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript
Benzinga · May 19, 2026
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · May 19, 2026
Gold Falls 1%; Amer Sports Earnings Top Views
Benzinga · May 19, 2026
Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings
Benzinga · May 19, 2026
Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline
Benzinga · May 19, 2026
UPDATE: InMed Pharmaceuticals To Merge With Mentari Therapeutics In All-Stock Deal Backed By $290M Private Placement, Combined Company Valued At $421.4M; InMed Shareholders to Own 1.51% Stake